ReviewVaccines2022
Cell-Based Manufacturing Technology Increases Antigenic Match of Influenza Vaccine and Results in Improved Effectiveness.
Review in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Differential Induction of Interferon-Stimulated Genes by Cell-Based Versus Egg-Based Quadrivalent Influenza Vaccines in Children During the 2018-2019 Season.The Journal of infectious diseases · 2024Trial
- Clinical and public health economic impact of rapid strain-matched vaccination in influenza pandemic mitigation: A UK-like population dynamic transmission model.Human vaccines & immunotherapeutics · 2026Article
- Strain Matching of Seasonal Influenza Vaccines and Emergence of Neuraminidase Inhibitor Resistance in China from 2015 to 2025.Vaccines · 2026Article
- The nanoemulsion adjuvant provides antigen dose-sparing effects and enhances maternal passive immune protection for the cell-cultured quadrivalent influenza virus subunit vaccine.Virology journal · 2026Article
- Article
- Superior Effectiveness and Estimated Public Health Impact of Cell- Versus Egg-Based Influenza Vaccines in Children and Adults During the US 2023-2024 Season.Infectious diseases and therapy · 2025Article
- Estimated Relative Effectiveness and Public Health Impact of Cell-Based Versus Egg-Based Influenza Vaccines During the 2022-2023 Season in the United States.Influenza and other respiratory viruses · 2025Article
- Understanding the Implications of Delaying Seasonal Influenza Vaccine Recommendations: An Industry Perspective.Vaccines · 2025Article
- Review
- Deficiency of IFNAR1 Increases the Production of Influenza Vaccine Viruses in MDCK Cells.Viruses · 2025Article
- The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses.Human vaccines & immunotherapeutics · 2024Review
- Innovations in cell culture-based influenza vaccine manufacturing - from static cultures to high cell density cultivations.Human vaccines & immunotherapeutics · 2024Review
- Structure-guided assembly of an influenza spike nanobicelle vaccine provides pan H1 intranasal protection.bioRxiv : the preprint server for biology · 2024Article
- Vaccines for Respiratory Viruses-COVID and Beyond.Vaccines · 2024Review
- Insect Cell-Based Quadrivalent Seasonal Influenza Virus-like Particles Vaccine Elicits Potent Immune Responses in Mice.Vaccines · 2024Article
- Relative Vaccine Effectiveness of Cell- vs Egg-Based Quadrivalent Influenza Vaccine Against Test-Confirmed Influenza Over 3 Seasons Between 2017 and 2020 in the United States.Open forum infectious diseases · 2024Article
- From single-cell cloning to high-yield influenza virus production - implementing advanced technologies in vaccine process development.Engineering in life sciences · 2024Article
- Advances in protein subunit vaccines against H1N1/09 influenza.Frontiers in immunology · 2024Review
- Article
- Global burden of influenza lower respiratory tract infections in older people from 1990 to 2019.Aging clinical and experimental research · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To ensure that vaccination offers the best protection against an infectious disease, sequence identity between the vaccine and the circulating strain is paramount. During replication of nucleic acid, random mutations occur due to the level of polymerase fidelity. In traditional influenza vaccine manufacture, vaccine viruses are propagated in fertilized chicken eggs, which can result in egg-adaptive mutations in the antigen-encoding genes. Whilst this improves infection and replication in eggs, mutations may reduce the effectiveness of egg-based influenza vaccines against circulating human viruses. In contrast, egg-adaptive mutations are avoided when vaccine viruses are propagated in Madin-Darby canine kidney (MDCK) cell lines during manufacture of cell-based inactivated influenza vaccines. The first mammalian cell-only strain was included in Flucelvax
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.